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Abstract
Background: Hyaline fibromatosis syndrome (HFS) is a recently introduced alternative term for two disorders that
were previously known as juvenile hyaline fibromatosis (JHF) and infantile systemic hyalinosis (ISH). These two
variants are secondary to mutations in the anthrax toxin receptor 2 gene (ANTXR2) located on chromosome 4q21.
The main clinical features of both entities include papular and/or nodular skin lesions, gingival hyperplasia, joint
contractures and osteolytic bone lesions that appear in the first few years of life, and the syndrome typically
progresses with the appearance of new lesions.
Methods: We describe five Lebanese patients from one family, aged between 28 and 58 years, and presenting with
nodular and papular skin lesions, gingival hyperplasia, joint contractures and bone lesions. Because of the particular
clinical features and the absence of a clinical diagnosis, Whole Genome Sequencing (WGS) was carried out on DNA
samples from the proband and his parents.
Results: A mutation in ANTXR2 (p. Gly116Val) that yielded a diagnosis of HFS was noted.
Conclusions: The main goal of this paper is to add to the knowledge related to the clinical and radiographic
aspects of HFS in adulthood and to show the importance of Next-Generation Sequencing (NGS) techniques in
resolving such puzzling cases.
Keywords: Juvenile hyaline fibromatosis, Infantile systemic hyalinosis, Hyaline fibromatosis syndrome, Whole
genome sequencing, Anthrax toxin receptor 2 gene
Background
Juvenile hyaline fibromatosis (JHF, OMIM # 228600) is a
rare inherited autosomal recessive disorder [1] that was
first described by McMurray as Molluscom fibrosum [2].
Clinically, it is characterized by skin lesions (nodules
and/or pearly papules); gingival hyperplasia; joint con-
tracture; abnormal growth of hyalinized fibrous tissues
of the head, neck and extremities; and bone lesions [3].
Affected individuals are usually asymptomatic at birth,
the onset of clinical signs occurs between 3 months and
4 years of age [4, 5], and these signs increase in severity
with age [6, 7]. Most people with JHF survive until the
fourth decade of life [8].
Infantile systemic hyalinosis (ISH, OMIM # 236490),
another rarer disorder, shares many similarities with JHF
[9, 10]. It is characterized by a more severe presentation
than JHF and has an early onset (first weeks or months
of life) and symptoms that include failure to thrive, short
stature, diffuse thickening of the skin, hyperpigmented
plaques over the joints, visceral involvement, persistent
diarrhea and recurrent infections, and death usually
occurs within the first 2 years of life [11–13].
Deleterious mutations of Anthrax toxin receptor 2 gene,
(ANTXR2; OMIM # 608041) have been shown to cause
both JHF and ISH [14–16]. The presence of a significant
overlap at the molecular, histological and clinical levels be-
tween JHF and ISH have led to the adoption by Nofal
et al. of an unifying taxonomy of “hyaline fibromatosis
syndrome or HFS”, signifying that both entities represent
* Correspondence: andre.megarbane@yahoo.fr; andre.megarbane@yahoo.fr
8Institut Jérôme Lejeune, 37, rue des Volontaires, Paris 75015, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Haidar et al. BMC Genetics  (2017) 18:3 
DOI 10.1186/s12863-017-0471-0
the same disorder but with different degrees of severity
[10, 17]. ANTXR2 encodes a 55 kDa type I transmem-
brane (TM) protein which comprises an extracellular N-
terminal von Willebrand A (vWA) domain, followed by
an immunoglobulin-like domain (Ig-like), a TM domain
and a cytosolic tail [18, 19]. This protein is responsible for
binding laminin and collagen IV via the vWA domain and
the consequent plays a role in basement membrane matrix
assembly and endothelial cell morphogenesis [15]. The Ig-
like domain contains two disulfide bonds that are essential
for proper ANTXR2 localization in the endoplasmic
reticulum [18]. The cytosolic tail contains multiple sites
for posttranslational modifications such as palmitoylation
[20], phosphorylation and ubiquitination [21].
Genotype-phenotype correlation studies have sug-
gested that the mutational spectrum might explain the
wide phenotypic variability. Milder phenotypes are asso-
ciated with in-frame and missense mutations within the
cytoplasmic domain, whereas the more severe forms are
caused by missense and truncating mutations in the
vWA domain and at least one insertion/deletion
mutation causing a translational frameshift. However,
this correlation is not always constant, thus indicating
that modifier genes and/or environmental elements can
be involved [15, 22].
Approximately 150 cases of HFS have been reported
in the literature [23]. Most of them were diagnosed in
early childhood [24], but only a few cases were investi-
gated in adults; the oldest patient was 51 years old [25].
In this paper, we report a large Lebanese family with
five HFS patients aged between 28 and 58 years. The
oldest patient (58 years) is described here. The aim of
this report is to augment the findings related to the
clinical, radiographic and differential diagnosis of HFS.
Methods
Clinical report
We identified one Lebanese Shiite family with three
branches from a small village in North Lebanon (Fig. 1).
All five patients were born to healthy consanguineous
couples. The pregnancies were not followed medically
but were reported to be without complications. For all
Fig. 1 Pedigree chart of the family and genomic DNA sequencing of the proband and both parents. The c.347G > T mutation in ANTXR2 was
homozygous in the proband and heterozygous in the parents
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patients, the skin eruptions and gingival enlargement
were first noticed at the age of 6 months, and the
nodules continued to gradually increase in number
and size.
At the time of physical examination, patient VI-3 was
42 years old, patient VI-4 was 36 years old, patient VI-5
was 30 years old, patient VI-10 was 28 years old and pa-
tient V-15 was 58 years old. Patients VI-3, VI-4, VI-10
and V-15 presented with an important postural deform-
ity, and had been in wheelchairs since they were 10 years
old, whereas patient VI-5 had a severe retardation of
physical growth and development that caused movement
difficulty.
The patients were thin with underdeveloped muscula-
tures. Cognitive development, hearing and eyesight were
noted to be normal in all patients.
Each patient was found to have recurrent, painless,
variable-sized nodules over the scalp, ear, lobules, post-
auricular folds, forehead, nose, upper lip, shoulder,
elbows, thorax, chest, back, fingers, perianal area, knee
and feet. Small, pearly papules were limited to the chin
and paranasal folds. The nose and ears were deformed
and bulbous, secondary to numerous tumors. All
patients had severe gingival hypertrophy covering the
teeth completely. Patients VI-10 and V-15 had flexion
contractures of the elbows, and fingers and hips and
knees, which resulted in a frog leg position (Fig. 2).
Swellings and deformities in the feet, especially in the
terminal phalanges of the toes, were also noted. The toe-
nails were thickened.
Hematological and biochemical investigations were
within normal limits. Only, patient VI-3 reported having
persistent diarrhea since the age of 2 years. The clinical
features of the present cases and of ISH and JHF, on the
basis of the work of Urbina et al.[10] are shown in Table 1.
A skeletal X-ray of patient VI-10 showed subcutaneous
soft tissue calcifications in the pinna of both ears and in
the parietal region of the scalp, radial bone bowing,
thoraco-lumbar scoliosis with paravertebral calcifications
at T10, T11 and T12 levels, deformity of the iliac bones,
thinned pubic rami, severe narrowing of the hip joints,
acetabular protrusion, erosion of joint spaces, coxo-
femoral ankylosis, thinned fibula, amyotrophy and cuta-
neous calcifications (Fig. 3).
The patients refused biopsies of their lesions.
DNA extraction and Whole Genome Sequencing (WGS)
Genomic DNA was extracted from peripheral blood
samples by standard salt-precipitation methods [26].
Whole genome sequencing was carried out on the DNA
of patient VI-4 and his parents with a HiSeq 2500
sequencer (Illumina, San Diego, CA, USA) at Sidra
Medical and Research Center - Qatar. Genomic libraries
were generated from 1 μg of genomic DNA using an
Illumina TruSeq DNA PCR-Free Sample Preparation
Kit. Genomic DNA was sheared using a Covaris system
Fig. 2 Clinical photographs of the patient V-15. Note the multiple skin nodules distributed on various body regions (mainly, ear and fingers) and
flexion contractures of the joints (wrists, knees, ankles and fingers)
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Fig. 3 X-rays of patient VI-10 showing (a) radial bone bowing and thin diaphyses, (b) deformity of the iliac bones, thinned pubic rami,
severe narrowing of the hip joints, acetabular protrusion, erosion of joint spaces, coxo-femoral ankylosis, thinned fibula, amyotrophy and
cutaneous calcifications, (c) thoraco-lumbar scoliosis with paravertebral calcifications at T10, T11 and T12 levels and (d) subcutaneous soft
tissue calcifications in the pinna of both ears and in the parietal region of the scalp












Papular skin lesions + + + + + + +
Thickened skin - - - - - + -
Gingival hyperplasia + + + + + + +
Perianal nodules + + + + + + +
large nodules/tumors + + + + + - +
Hyperpigmented plaques
Joints and bones
- - - - - + -
joint contractures + + + + + + +
Osteoporosis/osteopenia + + + + + + +
Osteolysis + + + + + + +
Persistent diarrhea + - - - + -
Recurrent infections - - - - - + -
Visceral involvement - - - - - + -
Short stature - - - - - + -
Prolonged survival + + + + + - +
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(Woburn, MA, USA). Isolated DNA fragment ends were
blunted, A-tailed and ligated with sequencing adaptors
with index sequences. Excess adapters and enzymes were
removed using AMPure beads (Beckman Coulter
Genomics, Danvers, MA, USA). Indexed libraries were
size-selected to the 350 bp range using bead-based cap-
ture, and the concentration of amplifiable fragments was
determined by qPCR, relative to sequencing libraries
with a known concentration. Normalized libraries were
clustered on a c-BOT machine, and 125 bp paired-end
sequencing was performed on the HiSeq 2500 system.
WGS data analyses
Raw data were mapped to the human genome reference,
build 19 (http://www.broadinstitute.org/ftp/pub/seq/ref-
erences/Homo_sapiens_assembly19.fasta), using BWA
aligner [27] version 0.7.7-r441, and variant calling was
performed using GATK [28] version 3.3.2. Rare variant
analysis was performed using the xbrowse tool (https://
xbrowse.broadinstitute.org/). For the trio, the model of
inheritance “autosomal recessive” was selected, with the
severity of the variant effect set to ‘moderate to high im-
pact’ (Nonsense, essential splice sites, missense frame-
shift and in frame), call quality as high (genotype
quality > 20 and allele balance ratio > 25%) and allele fre-
quency < 1% in 1000 genomes and The Exome Aggrega-
tion Consortium (ExAC) v0.3 datasets. The functional
consequences of amino acid substitutions were predicted
using various tools [29–32].
Sanger sequencing
Genomic sequence of ANTXR2 (NM_058172.5) was
obtained from UCSC Genomic Browser on Human.
Primers used for PCR amplification were designed using
Primer3 software (http://frodo.wi.mit.edu) to amplify the
region surrounding the mutation detected by WGS in
exon 4. PCR reactions were performed using Taq DNA
polymerase (Invitrogen Life Technologies, Carlsbad, CA,
USA). PCR fragments were run on 1% agarose gel. The
fragments were purified using « SIGMA-ALDRICH TM»
kit and then sequenced using the Big Dye_ Terminator v
1.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA). Sequence reaction was purified on
Sephadex G50 (Amersham Pharmacia Biotech, Foster
City, CA) and then loaded into an ABI 3100 system after
the addition of Hidi formamide. Electropherograms were
analyzed using Sequence Analysis Software version 5.2
(Applied Biosystems) and then aligned with the refer-
ence sequences using ChromasPro v1.7.6.1 (Technely-
sium, Queensland, Australia).
Results
WGS identified 2 mutations in ANTXR2 (NM_058172.5:
c.347G > T) and in zinc finger protein 618 (ZNF618)
(NM_133374.2: c.832G > T). The ANTXR2 mutation re-
sults in a substitution of glycine by valine, and the zinc
finger protein 618 (ZNF618) mutation leads to a prema-
ture stop codon. Both had damaging effects, according
to the majority of the effect predictors tested (Table 2).
Sanger sequencing confirmed the segregation of the
c.347G > T mutation in ANTXR2 with the disease within
the family (Fig. 1). The mutation was homozygous in the
affected patients, heterozygous in the parents and
heterozygous or not found in the unaffected siblings in
this family.
Discussion
Here, we report five adult patients from a consanguin-
eous Lebanese family, who presented with nodular skin
lesions, gingival hyperplasia, joint contractures and bone
lesions. By WGS, we identified 2 mutations: a mutation
in ZNF618 (c.832G > T) and a mutation in ANTXR2
(c.347G > T).
ZNF618, also known as KIAA1952 or NEDD10, is a
protein-coding gene located on chromosome 9q32 and
is implicated in transcriptional regulation. Association
studies have demonstrated that ZNF618 may be involved
in the occurrence of cleft lip [33], high blood pressure
[34], kidney diseases [35] and, in women, in brachial-
ankle pulse wave velocity and arterial stiffness [36, 37].
On the basis of these clinical characteristics, we ex-
cluded this gene as a candidate gene.
ANTXR2, also called the capillary morphogenesis pro-
tein gene-2 (CMG2) is located on chromosome 4q21
Table 2 Variants identified with the WGS analysis while running an autosomal recessive model using xbrowse. Damaging effects of
these mutations according to three softwares predictors was tested









Polyphen prediction: probably damaging
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and is implicated in basement membrane matrix and cell
morphogenesis [15]. Mutations of this gene have been
found to be responsible for HFS. After reviewing the
clinical features of our patients, we considered ANTXR2
to be a candidate gene responsible for the phenotype of
the patients studied here.
A clinical diagnosis of HFS was missed because of the
advanced age and status of the patients, the stage of the
disease, the severity of the clinical manifestations, and
incomplete knowledge of the syndrome’s pathogenesis.
The patients reported here had undergone multiple sur-
geries in infancy for the resection of cutaneous nodules,
but long-term regression was unlikely, and the tumors
continued to increase in size and number. Their parents
stopped treating the lesions, and no follow-up was per-
formed for economic reasons. Biopsies were refused by
the patients for many reasons, including pain and the
absence of treatment. WGS allowed us to diagnose the
disease, assess the genotype-phenotype correlations and
offer genetic counseling and prenatal diagnosis to the
people of the village.
Classification of HFS
HFS and inherited systemic hyalinosis represent the
same disorder, comprising two variants with severe
(ISH) and mild (JHF) forms of the disease.
Gilaberte et al. [6] have proposed 2 major and 3 minor
diagnostic criteria for JHF. The major criteria are cuta-
neous lesions (including nodules, tumors and plaques)
and gingival enlargement. The minor criteria include
joint contractures, osteolytic lesions and/or cortical ero-
sions, and a family history of JHF. In fact, the presence
of persistent diarrhea, hyperpigmented plaques, growth
retardation and death within the first 2 years of life are
more consistent with ISH. The severity and progression
of HFS vary among patients, and hence it is difficult to
classify a patient into a single class because many cases
of JHF are incorrectly identified as ISH, or vice versa
and mutations in the same gene underlie both syn-
dromes. Indeed, Bedford et al. [38] have described a se-
vere form of JHF, with persistent or repeated episodes of
diarrhea and death occurring in early infancy after sev-
eral infections yet with no subcutaneous nodules. Hata-
mochi et al. [39] have reported a 6-year-old girl who was
diagnosed with a severe form of JHF and presented with
confluent papules and nodules, recurrent respiratory
tract infections and chronic diarrhea since birth. Dhin-
gra et al. [40] have reported a 3-year-old girl who pre-
sented with recurrent episodes of diarrhea and was
diagnosed as having a case of JHF. ISH patients with
atypical prolonged survival have also been reported [41].
Kawasaki et al. [42] have reported an elderly woman
with JHF who died from aspiration pneumonia. For
these reasons, we prefer to classify our patients as having
HFS, which includes both disorders, as proposed by
Nofal et al. [17].
In contrast, Nofal et al. [17] have classified HFS into
three grades according to the severity of organ involve-
ment: G1: mild, G2: moderate and G3: severe. On the
basis of this gradation, the mild type presents with only
skin involvement and gingival hypertrophy, the moderate
type shows additional joint contractures and bone le-
sions, and the severe type has manifestations resulting
from organ involvement, such as persistent diarrhea and
recurrent pulmonary infections. Denadai et al. [22] have
added a new lethal grade (G4) for patients with organ
failure and/or septicemia. In the family studied here, pa-
tients VI-4, VI-5, VI-10 and V-15 can be classified as
JHF grade 2 and patient VI-3 as ISH grade 3, thus dem-
onstrating the difficulty of clearly differentiating these
subclasses.
Prevalence
HFS is a rare genetic disorder, but it has been docu-
mented in families of different ethnic backgrounds on
several continents [11]. The life expectancy of patients
with HFS syndrome varies from early death in childhood
to normal survivorship. The oldest known patient
(58 years) is reported here.
Diagnosis
The diagnosis of this syndrome is based on the clinical
features and/or the presence of a molecular diagnosis.
Clinical diagnosis
The clinical features associated with HFS syndrome con-
sist of multiple subcutaneous skin nodules/papules, gin-
gival hypertrophy and joint contractures and may be
accompanied by systemic symptoms.
The specific pathogenesis of HFS also remains unclear,
but some authors have suggested that it results from an
abnormality in type IV or VI (α1, α2 and α3 chains)
collagen [3, 43] or defective glycosaminoglycan forma-
tion [44, 45].
Skeletal radiographs in adults To our knowledge, 33
cases of HFS have been reported in adults, of which 14
with X-ray findings. In 13 of these 14 cases, joint con-
tractures, osteolytic destruction of the skull, of the large
joints, of the long bones and of the extremities, triangu-
lar carpal bones and an isolated cortical erosion of man-
dibular bone and calcifications in the subcutaneous
tumors were noted [4, 8, 16, 22, 25, 42, 46–52]. In one
patient, no calcifications or bone involvement were
noted on radiography [53].
Magnetic resonance imaging (MRI) of HFS lesions has
rarely been described in adults and shows a hypointense,
central, radiating scar and heterogeneous signal
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intensity. After the administration of a gadolinium con-
trast medium, the lesion showed diffuse enhancement,
with the exception of the central scar and discrete
enhancement of subcutaneous masses in contrasted
phases [8, 51, 53].
Computed tomography (CT) of the head has dem-
onstrated a normal aspect [51] or an abnormal
bucco-lingual expansion with lingual cortical erosion
[46], calcifications within the subcutaneous tumors,
and a soft tissue mass extending from the hard palate
into the nasal cavity and maxillary sinus [42]. En-
hanced CT has revealed dye uptake in the subman-
dibular and cervical lymph nodes bilaterally [42].
Brain CT has shown small ischemic regions in the
right periventricular aspect, mild brain atrophy and
extracranial tumor masses in the soft tissues of the
right peritemporal and occipital aspects [47].
Histopathology The histopathologic features of this dis-
ease include a normal epidermis with few inflammatory
cells in the dermis and minor pigmentary incontinence.
Deposits of an amorphous, homogeneous and eosino-
philic, hyaline substance (periodic acid–Schiff positive),
can be found in the papillary and reticular dermis, ac-
companied by a proliferation of spindle cells without
atypia [10, 22].
Electron microscopic studies have shown stromal de-
posits of a fibrillogranular material focally displaying a
banding pattern similar to that of type VI collagen and
fibroblasts with prominent Golgi complexes, dilated
endoplasmic reticulum, multi vesicular bodies and vesi-
cles filled with a fibrillogranular material [3, 10, 43]. Cal-
cospherules, defined as calcium-containing lamellar
body have been described in JHF by Ko and Barr in
2003 [54].
Intestinal biopsy and imaging The results of biopsy
cases from patients with gastrointestinal signs include
villous atrophy, edema, lymphangiectasia and hyalinosis.
Rapid transit time has been described in real-time
upper-gastrointestinal imaging investigations [55].
Immune system deficit Deficits of the humoral and cel-
lular branches of the immune system have been ob-
served [56].
Laboratory studies Laboratory examination may dem-
onstrate a normal [22, 42, 57, 58] or abnormal aspect,
such as an elevation of the Erythrocyte Sedimentation
Rate (ESR) [47, 51, 59], thrombocytosis [60], mild
anemia [4, 47, 51], or an elevation of serum albumin
[61] or alkaline phosphatase [62].
Molecular diagnosis
ANTXR2 is the only gene in which pathogenic variants
are known to cause HFS. Mutations of this gene disrupt
the formation of basement membranes. This disruption
may allow the hyaline material to leak from plasma com-
ponents through the basement membrane into the peri-
vascular space, thus explaining the histological features
of HFS [15].
As shown in Table 3, 41 different ANTXR2 mutations
have been described. Yan et al. [63] have reported that
three frameshift mutations (c.1073-1074insC, c.1073-
1074insCC and c.1074delT) represent approximately
60% of all pathogenic alleles. The incidence of insertions
and deletions at positions 1073–1074 is probably due to
its proximity to a low-complexity, GC-rich region en-
coding a stretch of proline residues that may constitute
a vulnerable site for errors during DNA replication. The
mutation p. Gly116Val identified in all patients in this
study has previously been reported by Tümer et al. [64]
in an 11-month-old Turkish girl with HFS. This muta-
tion is located in the vWA domain and may damage lig-
and binding, not plasma membrane targeting, thus
causing a severe manifestation of HFS. A comparison
between the clinical signs of the patients in this study
and the girl with the same mutation shows some differ-
ences: the girl presented with short stature and gingival
hypertrophy and developed recurrent infections. She did
not present with any visceral involvement. X-ray images
did not show any osteolytic lesions [64]. These differ-
ences may be explained by the differences in age, and/or
environmental factors.
Mode of inheritance and genetic counseling
An autosomal recessive mode of inheritance has been
established for HFS. Therefore, the risk for a parental
carrier to have an affected offspring is 25%.
Treatment and follow-up
Currently, only symptomatic treatments for HFS are
available. Early surgical excision of the lesions is recom-
mended for functional and cosmetic improvement [9,
52]. However, the lesions may recur and new lesions
may appear [4, 52, 65, 66]. Intralesional steroid injec-
tions have been suggested because they can reduce the
size of early lesions [9]. Capsulotomy, physiotherapy,
treatment with cortisone and adrenocorticotropin
(ACTH) have found modest success in the treatment of
joint contractures [67]. Radiotherapy is not effective [10,
68]. Oral D-penicillamine may improve joint mobility
and flexibility [65, 69]. Nonsteroidal anti-inflammatory
drugs and opiates may be used to control pain and im-
prove the quality of life [9, 70]. Gingival hyperplasia re-
quires special dental care and many dental consultations
to promote strict oral hygiene [71]. Gingivectomy may
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improve the quality of oral hygiene and nourishment by
improving mastication and preventing gingival blood
loss [72, 73]. Ablative laser surgery may be a reasonable
choice and may be useful, at least as an adjunctive treat-
ment [74]. In context of genetic therapies for this debili-
tating disorder, Deuquet et al. [18] have revealed that
proteasome inhibitors may be potential therapeutic
drugs for HFS patients with mutations in the ectodo-
main of ANTXR2.
Conclusions
We report a Lebanese family with five adult patients
with HFS. WGS showed an ability to establish a diagno-
sis in such puzzling cases in which the clinical signs are
atypical or very severe for the classical phenotype. HFS
is still a poorly understood disease with a severity that
ranges from being lethal during early childhood to
chronic at a later age. More studies to find an effective
treatment are essential. An accurate diagnosis of the dis-
ease requires an exhaustive analysis of the radiologic and
histopathological clinical findings, and genetic studies
are required for family planning and counseling.
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